We passionately improve health
Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies.
THERAPEUTIC AREA
Metabolic
425
million adult people
in the world are living with diabetes, with Type 2 diabetes accounting for 90% of all cases1
About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases1. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, we are also focused on cardiometabolic indications with a high unmet medical need.
Learn more
1 Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (link is external) (accessed April 2018)
Learn more
Cardiovascular
Cardiovascular disease
including
heart disease
and stroke
is a major
global health concern and the leading cause of death and disability worldwide1
Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide1. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).
Learn more
1 Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.
Learn more
Oncology
Taking Cancer on
At Boehringer Ingelheim, we believe this can be the generation that redefines many cancers as curable diseases. We want to be part of this transformation.
Lung cancer remains the most common cause of cancer deaths worldwide for men, and the second most common for women.1 It is estimated that in 2020 there will be 2.3 million new lung cancer cases and 2.0 million resulting deaths worldwide.2 Although patient outcomes are better if the disease is diagnosed in its early stages, the 5-year survival rate for metastatic disease remains less than 5%.3 Non-small cell lung cancer (NSCLC) is the most common tumour type, accounting for approximately 85% of lung cancers.3
At Boehringer Ingelheim, we are providing new hope for patients by taking cancer on. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.
1. Torre LA, et al. CA Cancer J Clin 2015;65(2):87–108.
2. Ferlay J, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr/Pages/burden_sel.aspx (Accessed: 3 July 2017).
3. Schvartsman G, et al. Ther Adv Med Oncol 2016;8(6):460–73.
Learn more
At Boehringer Ingelheim, we are providing new hope for patients by taking cancer on. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.
1. Torre LA, et al. CA Cancer J Clin 2015;65(2):87–108.
2. Ferlay J, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr/Pages/burden_sel.aspx (Accessed: 3 July 2017).
3. Schvartsman G, et al. Ther Adv Med Oncol 2016;8(6):460–73.
Learn more
Respiratory
Boehringer Ingelheim
has over 90 years
of heritage
in managing
respiratory disease
Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life
Boehringer Ingelheim has over 90 years of heritage in managing respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.
Learn more
Learn more
Inflammation
Boehringer Ingelheim
Inflammation:
Pioneering Science,
Inspired
By Patients
We won’t rest until we can give people the chance to live the life they want.
Living with fibrotic and inflammatory diseases greatly impacts patients’ lives. These patients are our guide, partner and inspiration as we redefine treatment paradigms. As a family-owned company, we can plan long-term. Our goal is to discover and develop first-of-their-kind therapies that target, repair and prevent many fibrotic and inflammatory diseases. By building on long-term collaborations, we strive to bring treatment breakthroughs to patients in the shortest time.
Learn more
Learn more
